Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"; continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; education and awareness of cardiovascular disease; all provisions of HR351 and S351 "Protecting Seniors' Access to Medicare Act of 2013"; issues related to health care reform; general issues related to awareness of Ebola; and all issues related to the 21st Century Cures Initiative.
Education and awareness regarding illegal compounding of veterinary drugs for animals.
All provisions of HR 2052 and S 1023 "Global Investment in American Jobs Act of 2013"
Extension of the U.S. R&D tax credit. Issues related to Corporate Tax Reform. Provisions of H.R.2535 and S.1647 "Restoring Access to Medication Act of 2013." HR 4718 " To Amend the Internal Revenue Code of 1986 to Modify and Make Permanent Bonus Depreciation". HR 3474 "Hire more Heroes Act of 2014."
Issues related to the Medicaid drug rebate policy; issues related to the Medicare Part B reimbursement of prescription drugs; and general issues related to Medicare Part D program.
General issues related to the 340B Federal Drug Pricing Program
Duration: November 1, 2007
to
January 1, 2015
General Issues: Health Issues , Animals , Economics/Economic Development , Taxation/Internal Revenue Code , Medicare/Medicaid , Pharmacy , Medical/Disease Research/Clinical Labs , Copyright/Patent/Trademark , Budget/Appropriations
Spending: about $970,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: House of Representatives, U.S. Senate, Y
Y
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2015
TCH Group, LLC terminated an engagement in which they represented Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) on April 16, 2015.
Original Filing: 300717382.xml
4th Quarter, 2014
In Q4, TCH Group, LLC lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $40,000. The report was filed on Jan. 15, 2015.
Original Filing: 300696489.xml
Lobbying Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"; continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; education and awareness of cardiovascular disease; all provisions of HR351 and S351 "Protecting Seniors' Access to Medicare Act of 2013"; issues related to health care reform; general issues related to awareness of Ebola; and all issues related to the 21st Century Cures Initiative.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Education and awareness regarding illegal compounding of veterinary drugs for animals.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
All provisions of HR 2052 and S 1023 "Global Investment in American Jobs Act of 2013"
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Extension of the U.S. R&D tax credit. Issues related to Corporate Tax Reform. Provisions of H.R.2535 and S.1647 "Restoring Access to Medication Act of 2013." HR 4718 " To Amend the Internal Revenue Code of 1986 to Modify and Make Permanent Bonus Depreciation". HR 3474 "Hire more Heroes Act of 2014."
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Medicaid drug rebate policy; issues related to the Medicare Part B reimbursement of prescription drugs; and general issues related to Medicare Part D program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General issues related to the 340B Federal Drug Pricing Program
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2014
In Q3, TCH Group, LLC lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $40,000. The report was filed on Oct. 17, 2014.
Original Filing: 300680084.xml
Lobbying Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014." General issues related to the 21st Century Cures Initiative.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Education and awareness regarding illegal compounding of veterinary drugs for animals.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
All provisions of HR 2052 and S 1023 "Global Investment in American Jobs Act of 2013"
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Extension of the U.S. R&D tax credit. Issues related to Corporate Tax Reform. Provisions of H.R.2535 and S.1647 "Restoring Access to Medication Act of 2013." HR 4718 " To Amend the Internal Revenue Code of 1986 to Modify and Make Permanent Bonus Depreciation". HR 3474 "Hire more Heroes Act of 2014."
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Medicaid drug rebate policy; issues related to the Medicare Part B reimbursement of prescription drugs; and issues related to Medication Therapy Management.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General issues related to the 340B Federal Drug Pricing Program
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2014
In Q2, TCH Group, LLC lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $40,000. The report was filed on July 17, 2014.
Original Filing: 300660124.xml
Lobbying Issues
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014."
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Education and awareness regarding illegal compounding of veterinary drugs for animals.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
All provisions of HR 2052 and S 1023 "Global Investment in American Jobs Act of 2013"
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Extension of the U.S. R&D tax credit. Issues related to Corporate Tax Reform. Provisions of H.R.2535 and S.1647 "Restoring Access to Medication Act of 2013." HR 4718 " To Amend the Internal Revenue Code of 1986 to Modify and Make Permanent Bonus Depreciation" and maintaining the orphan drug tax credit. HR 3474 "Hire more Heroes Act of 2014."
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Medicaid drug rebate policy; issues related to the Medicare Part B reimbursement of prescription drugs; and issues related to Medication Therapy Management.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General issues related to the 340B Federal Drug Pricing Program
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2014
In Q1, TCH Group, LLC lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $40,000. The report was filed on April 18, 2014.
Original Filing: 300641371.xml
Lobbying Issues
Education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; S.1871 "Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Improvement Act of 2013." H.R.1024 and S.557 "Medication Therapy Management Empowerment Act of 2013." General issues related to FDA and NIH funding; Awareness and education about Sanofi's Access to Medicines Program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Education and awareness regarding illegal compounding of veterinary drugs for animals.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
All provisions of HR 2052 and S 1023 "Global Investment in American Jobs Act of 2013"
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Extension of the U.S. R&D tax credit.
Issues related to Corporate Tax Reform.
Provisions of H.R.2535 and S.1647 "Restoring Access to Medication Act of 2013"
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the Medicaid rebate policy; coverage and reimbursement for the Medicare Part D prescription drug benefit and the Medicare Part D annual call letter; general issues related to reform of the Medicare Part D program; and issues related to the Medicare Part B reimbursement of prescription drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General issues related to the 340B Federal Drug Pricing Program
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2013
In Q4, TCH Group, LLC lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $40,000. The report was filed on Jan. 16, 2014.
Original Filing: 300616096.xml
Lobbying Issues
Education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; FDA funding; NIH funding; general issues related to diabetes awareness; H.R.2094 and S.1503; general issues related to School Access to Emergency Epinephrine Act. S.1871 "Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Improvement Act of 2013." H.R.1024 and S.557 "Medication Therapy Management Empowerment Act of 2013."
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Education and awareness of issues related to the compunding of medications for animal health; all provisions of HR 1407 "Animal Drug User Fee Amendments of 2013" Education and awareness regarding illegal compounding of veterinary drugs for animals; all provisions of S 622 "Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013"
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
All provisions of HR 2052 and S 1023 "Global Investment in American Jobs Act of 2013"
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Extension of the U.S. R&D tax credit; extending and maintaining the orphan drug tax credit.
Issues related to Corporate Tax Reform.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement for those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit; and general issues related to the Medicare Part D program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2013
In Q3, TCH Group, LLC lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $40,000. The report was filed on Oct. 17, 2013.
Original Filing: 300597010.xml
Lobbying Issues
Education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; FDA funding; NIH funding; general issues related to diabetes awareness; H.R.2094 and S.1503; issues related to the Independent Payment Advisory Board; general issues related to School Access to Emergency Epinephrine Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Education and awareness of issues related to the compunding of medications for animal health, including all provisions of S 959 "Pharmaceutical Compounding Quality and Accountability Act"; all provisions of HR 1407 "Animal Drug User Fee Amendments of 2013" Education and awareness regarding illegal compounding of veterinary drugs for animals; all provisions of S 622 "Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013"
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
All provisions of HR 2052 and S 1023 "Global Investment in American Jobs Act of 2013"
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Extension of the U.S. R&D tax credit; extending and maintaining the orphan drug tax credit
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement for those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit; and general issues related to the Medicare Part D program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2013
In Q2, TCH Group, LLC lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $40,000. The report was filed on July 17, 2013.
Original Filing: 300574697.xml
Lobbying Issues
Education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; FDA funding; NIH funding; general issues related to diabetes awareness; all provisions of S 557 "Medication Therapy Management Empowerment Act of 2013"; all provisions of S 596 "Fostering Independence Through Technology Act of 2013"; issues related to the Independent Payment Advisory Board; general issues related to School Access to Emergency Epinephrine
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Education and awareness of issues related to the compunding of medications for animal health, including all provisions of S 959 "Pharmaceutical Compounding Quality and Accountability Act"; all provisions of HR 1407 "Animal Drug User Fee Amendments of 2013" Education and awareness regarding illegal compounding of veterinary drugs for animals; all provisions of S 622 "Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013"
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
All provisions of HR 2052 and S 1023 "Global Investment in American Jobs Act of 2013"
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
Extension of the U.S. R&D tax credit; extending and maintaining the orphan drug tax credit; and adding quadrivalent influenza vaccine formulation to the Vaccine Injury Compensation Program.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement for those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit; and general issues related to the Medicare Part D program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2013
In Q1, TCH Group, LLC lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $40,000. The report was filed on April 19, 2013.
Original Filing: 300555993.xml
Lobbying Issues
S.77 "Prescription Drug and Health Improvement Act of 2013" - all provisions; S117, "Medicare Prescription Drug Price Negotiation Acot of 2013" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of dengue; FDA funding; reauthorization of Pandemic and All HazardsPreparation Act; general issues related to the importation of pharmaceutical products; issues related to chronic disease treatment adherence with the CMS Innovation Center; general issues related to School Access to Emergency Epinephrine; and issues related to the data exclusivity period for generic biologics.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Education and awareness regarding illegal compounding of veterinary drugs for animals; general issues related to the reauthorization of the Animal Drug User Fee Act; HR1150 "Preservation of Antibiotics for Medical Treatment Act of 2013"; HR 820 "Delivering Antimicrobial Transparency in Animals Act of 2013"
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2012
In Q4, TCH Group, LLC lobbied for Sanofi US Services Inc. (Formerly known as sanofi-aventis U.S. Inc.) , earning $40,000. The report was filed on Jan. 18, 2013.
Original Filing: 300532764.xml
Lobbying Issues
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board; "HR 4223 "Strenghthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "Safe Doses Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR 2405 and S 1855 "Pandemic and All Hazards Preparation ActReauthorization of 2011" - all provisions; HR 3627 and S 1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of pandemic and biodefence funding in FY2012 and related international intellectual property issues; and education and awareness of dengue.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to changing reimbursement under the Medicare Part B program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General issues related to foreign direct investment in the United States, including all provisions of S. 3274 and H.R. 5910 "Global Investment in American Jobs Act of 2012".
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Economics/Economic Development
Lobbying Issues
S 810 and HR 1513 "Great Ape Protection and Cost Savings Act of 2011" - all provisions.
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2012
In Q3, TCH Group, LLC lobbied for sanofi-aventis U.S. Inc. , earning $40,000. The report was filed on Oct. 18, 2012.
Original Filing: 300511389.xml
Lobbying Issues
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IBAP); awareness & issues related to diabetes and patient access to diabetes care; general issues related to prescription drug safety; H.R. 2529 "Restoring Access to Medication Act" - all provisions; H.R. 3627 and S. 1884 "School Access to Emergency Epinephrine Act" - all provisions; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenze pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; H.R. 2405 and S. 1855 education and awareness of Dengue; H.R. 4223 "Strengthening and Focusing Enforcement to deter Organized Stealing and Enhance Safety Act of 2012" or "Safe Doses Act"; H. Res. 295 "Promoting increased awareness, diagnosis and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with the disease; H.R. 436 "Healthcare Cost Reduction Act of 2012"; awareness and issues related to diabetes and patient access to diabetes care.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to changing reimbursement for physicians under the Medicare Part B program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General issues related to foreign direct investment in the United States, including all provisions of S. 3274 and H.R. 5910 "Global Investment in American Jobs Act of 2012".
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Economics/Economic Development
2nd Quarter, 2012
In Q2, TCH Group, LLC lobbied for sanofi-aventis U.S. Inc. , earning $40,000. The report was filed on July 16, 2012.
Original Filing: 300484939.xml
Lobbying Issues
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act"; awareness & issues related to diabetes and patient access to diabetes care; general issues related to prescription drug safety; HR2529 "Restoring Access to Medication Act" - all provisions; HR 3627 and S1884 "School Access toEmergency Epinephrine Act" - all provisions; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenze pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of Dengue; all provisions of S1002 "Safe Doses Act."
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General discussion regarding the reauthorization of the Prescription Drug User Fee Act (PDUFA)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General issues related to foreign direct investment in the United States, including all provisions of S 3274 and HR 5910 "Global Investment in American Jobs Act of 2012"
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Economics/Economic Development
1st Quarter, 2012
In Q1, TCH Group, LLC lobbied for sanofi-aventis U.S. Inc. , earning $40,000. The report was filed on April 18, 2012.
Original Filing: 300463454.xml
Lobbying Issues
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IBAP); awareness & issues related to diabetes and patient access to diabetes care; general issues related to prescription drug safety; HR2529 "Restoring Access to Medication Act" - all provisions; HR2245 "Preserving Access to Life-Saving Medications Act of 2011" - all provisions; HR 3627 and S1884 "School Access toEmergency Epinephrine Act" - all provisions; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenze pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of Dengue; all provisions of S1002 "Safe Doses Act"; awareness & issues related to patient access to care for Dengue; and all provisions of draft legislation "Immunization Improvements Act of 2011."
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to changing reimbursement for physicians under the Medicare Part B program
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General discussion regarding the reauthorization of the Prescription Drug User Fee Act (PDUFA)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2011
In Q4, TCH Group, LLC lobbied for sanofi-aventis U.S. Inc. , earning $40,000. The report was filed on Jan. 19, 2012.
Original Filing: 300443080.xml
Lobbying Issues
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IBAP); awareness & issues related to diabetes and patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to preventavoidable hospitalizations associated with this disease"; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of Dengue; general issues related to prescription drug safety and the importation of prescription drugs; and all provisions of S1002 "Safe Doses Act"; awareness & issues related to patient access to care fo C. Difficile; awareness about the company's Access to Medicines Program; awareness & issues related to patient access to care for Dengue
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General issues related to the Medicare Part D Program, issues related to provider reimbursement for the administration of vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General discussion regarding the reauthorization of the Prescription Drug User Fee Act (PDUFA)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2011
In Q3, TCH Group, LLC lobbied for sanofi-aventis U.S. Inc. , earning $40,000. The report was filed on Oct. 14, 2011.
Original Filing: 300414379.xml
Lobbying Issues
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including all provisions of HR605 and S312 "Patients' Freedom to Choose Act," the Medication Therapy Management Program, transitions of care, and the Independent Payment Advisory Board (IPAB); awareness and issues related to patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promotingincreased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 and intellectual property issues in the WHO proposal; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of the company's global Access to Medicines Program; education and awareness of dengue; issues related to the Section 317 Program for vaccines; general issues related to prescription drug safety; and all provisions of S1002 "Safe Doses Act".
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General issues related to the Medicare Part D Program
Lobbying Issues
S23 "America Invents Act" (formerly "Patent Reform Act of 2011"), HR1249, The American Invents Act (PL112-29).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
General discussion regarding the reauthorization of the Prescription Drug User Fee Act (PDUFA); and education and awareness of vaccine production and infrastructure needs
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2011
In Q2, TCH Group, LLC lobbied for sanofi-aventis U.S. Inc. , earning $40,000. The report was filed on July 20, 2011.
Original Filing: 300400175.xml
Lobbying Issues
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including all provisions of HR605 and S312 "Patients' Freedom to Choose Act," the Medication Therapy Management Program, transitions of care, and the Independent Payment Advisory Board (IPAB); awareness and issues related to patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promotingincreased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 and intellectual property issues in the WHO proposal; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of the company's global Access to Medicines Program; education and awareness of dengue; issues related to the Section 317 Program for vaccines; general issues related to prescription drug safety; and all provisions of S1002 "Safe Doses Act".
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
General issues related to the Medicare Part D Program
Lobbying Issues
S23 "America Invents Act" (formerly "Patent Reform Act of 2011"), HR1249, The American Invents Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
General discussion regarding the reauthorization of the Prescription Drug User Fee Act (PDUFA); and education and awareness of vaccine production and infrastructure needs
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2011
In Q1, TCH Group, LLC lobbied for sanofi-aventis U.S. Inc. , earning $40,000. The report was filed on April 15, 2011.
Original Filing: 300365604.xml
Lobbying Issues
Comparative effectiveness, including issues related to the Patient Centered Research Institute, issues related to limitations on the use of Health Savings Accounts for over-the-counter medicines, repeal and defunding efforts, & general issues regarding implementation of HR3590 "The Patient Protection and Affordable Care Act" including the Medication Therapy Management Program transitions of care; awareness and issues related to patient access to diabetes care; awareness and issues related to patientatrial fibrillation care; all provisions of S668 "Health care Bureaucrats Elimination Act" and HR452 "Medicare Decisions Accountability Act of 2011"; issues related to efforts to move pseudoephedrine products to prescription drug status; section 401 of S174 "Healthy Lifestyles and Prevention (HeLP) America Act"; and issues related to pandemic influenza and biodefense funding. The Reauthorization of the Prescription Drug User Fee Act (PDUFA).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Provisions relateed to a mens rea requirement in HR675 "Strengthening Medicare Ant-Fraud Measures Act of 2011".
Lobbying Issues
S23 "America Invents Act" (formerly "Patent Reform Act of 2011"), HR1249, The American Invents Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2010
In Q4, TCH Group, LLC lobbied for sanofi-aventis U.S. Inc. , earning $20,000. The report was filed on Jan. 20, 2011.
Original Filing: 300351285.xml
Lobbying Issues
Comparative effectiveness, including issues related to the Patient Centered Research Institute, and general issues regarding implementation of HR 3590 "The Patient Protection and Affordable Care Act"; information and awareness of the availability of new treatment options for cancer patients; and awareness and issues related to patient access to diabetes care.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the reimbursement of influenza vaccines in the Medicare Part B program.
Lobbying Issues
Extension of the U.S. R&D tax credit and all such provisions in HR4853 "Tax Relief, Unemployment Insurance Reauthorization, and Job Creation Act of 2010" and HR422 "To amend the Internal Revenue Code of 1986 to extend research credit through 2010 and to increase and make permanent the alternative simplified research credit"; and S1203 "Grow Research Opportunities with Tax Credits' Help Act" or "GROWTH Act"
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
All provisions of S 369 "Preserve Access to Affordable Generics Act" and inlcuding this bill as amended to be included in S3677 "Financial Services and General Government Appropriations Act, 2011"
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2010
In Q3, TCH Group, LLC lobbied for sanofi-aventis U.S. Inc. , earning $20,000. The report was filed on Oct. 19, 2010.
Original Filing: 300320121.xml
Lobbying Issues
Comparative effectiveness research, including issues related to the Patient Centered Research Institute, and general issues regarding the implementation of HR3590 "The Patient Protection and Affordable Care Act"; information and awareness of the availability of new treatment options for cancer patients; prescription drug safety and heparin including related issues through a follow-on biologics regulatory pathway; issues related to influenza vaccine coverage in the Medicare Part D program; awareness and issues related to patient Access to diabetes care.
Lobbying Issues
Issues related to the reimbursement of influenza vaccines in the Medicare Part B program.
Lobbying Issues
Extension of the R&D tax credit and all such provisions in HR422 "To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit"; and S1203 "Grow Research Opportunities with Tax Credits' Help Act" or "GROWTH Act".
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
All provisions of S 369 "Preserve Access to Affordable Generics Act" and inlcuidng this bill as amended to be included in S3677 "Financial Services and General Government Appropriations Act, 2011"; and S515 "Patent Reform Act of 2009"- all provisions.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2010
In Q2, TCH Group, LLC lobbied for sanofi-aventis U.S. Inc. , earning $20,000. The report was filed on July 19, 2010.
Original Filing: 300294252.xml
Lobbying Issues
Comparative effectiveness research and general issues regarding the implementation of HR3590 "The Patient Protection and Affordable Care Act"; information and awareness of a Community Health Liaison Program; information and awareness of the availability of new treatment options for cancer patients; prescription drug safety and heparin including related issues through a follow on biologics regulatory pathway
Lobbying Issues
Medicare Part B reimbursement issues; the Medicaid Federal Medical Assistance Percentage (FMAP).
Lobbying Issues
Extension of the R&D tax credit and all such provisions in HR422 "To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit"; and S1203 "Grow Research Opportunities with Tax Credits' Help Act" or "GROWTH Act".
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S369 "Protecting Access to Affordable Generic Drugs Act of 2009"- all provisions; S515 "Patent Reform Act of 2009"- all provisions.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2010
In Q1, TCH Group, LLC lobbied for sanofi-aventis U.S. Inc. , earning $20,000. The report was filed on April 20, 2010.
Original Filing: 300272323.xml
Lobbying Issues
HR3692 "To provide affordable, quality health care for all Americans and reduce growth in health care spending, and for other purposes"; HR 4872 "Health Care and Education Reconciliation Act of 2010"; HR3590 "The Patient Protection and Affordable Care Act"- provisions related to follow-on biologics, comparative effectiveness research, 340B programs and the Independent Payment Advisory Board; issues related to prescription drug safety and heparin; issues related to cancer awareness and access to treatment.
Lobbying Issues
Issues related to vaccine administration payment under the Medicaid program.
Lobbying Issues
Extension of the R&D tax credit and all such provisions in HR4213, "American Workers, State, and Business Relief Act of 2010"; HR422 "To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit"; and S1203 "Grow Research Opportunities with Tax Credits' Help Act" or "GROWTH Act".
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
All provisions of S369 "Protecting Access to Affordable Generic Drugs Act of 2009"; and HR 1706 "Protecting Consumer Access to Generic Drugs Act of 2009"; all provisions of S515 "The Patent Reform Act of 2009" and HR 1260 "The Patent Refrom Act of 2009"; HR 4872, "Health Care & Education Reconciliation Act of 2010" provisions related to patent settlements.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2009
In Q4, TCH Group, LLC lobbied for sanofi-aventis U.S. Inc. , earning $20,000. The report was filed on Jan. 19, 2010.
Original Filing: 300239469.xml
Lobbying Issues
Provisions and issues related to patient access to and the coverage, payment, and pricing of pharmaceuticals, provisions related to intellectual property and issues related to a regulatory pathway and reimbursement for follow-on biologics, issues related to cancer awareness and access to treatment, issues and provisions related to the 340B federal Safety Bet Drug Pricing Programs, isses and provisions related to comparative effectiveness, and issues and provisions related to the Independent Medicare Advisory Committeein HR 3590 "The Patient Protection and Affordable Care Act." All provisions of SAmdt2952 to HR 3590. General issues related to the Medicare Part D program including patient access to pharmaceuticals, issues related to awareness of atrial fibrillation and access to treatment, issues related to cancer awareness and access to treatment
Lobbying Issues
Issues related to the Medicaid Program
Medicare Part B Reimbursement
Lobbying Issues
Extension of the U.S. R&D tax credit including all such provisions in HR 422 "To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit. International tax treaties and the ratification of the Second Protocol to the Income Tax Treaty between the U.S. and France.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
All provisions of S369 "Protecting Access to Affordable Generic Drugs Act of 2009"; and HR 1706 "Protecting Consumer Access to Generic Drugs Act of 2009"; all provisions of S515 "The Patent Reform Act of 2009" and HR 1260 "The Patent Refrom Act of 2009"
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2009
In Q3, TCH Group, LLC lobbied for sanofi-aventis U.S. Inc. , earning $20,000. The report was filed on Oct. 20, 2009.
Original Filing: 300215491.xml
Lobbying Issues
HR3200 "America's Affordable Health Choices Act"; and S1769 "Affordable Health Choices Act"; General issues related to the Medicare Part D program and issues related to awareness of atrial fibrillation and access to treatment.; All provisions of HR2502 "To amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes"; All provisions ofH. Res. 231 "Supporting the goals and ideals of 'Deep Vein Thrombosis Awareness Month"
Lobbying Issues
Issues related to the Medicaid Program
Medicare Part B Reimbursement
Lobbying Issues
Extension of the U.S. R&D tax credit including all such provisions in HR 422 "To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit. International tax treaties and the ratification of the Second Protocol to the Income Tax Treaty between the U.S. and France.
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
All provisions of S369 "Protecting Access to Affordable Generic Drugs Act of 2009"; and HR 1706 "Protecting Consumer Access to Generic Drugs Act of 2009"; all provisions of S515 "The Patent Reform Act of 2009" and HR 1260 "The Patent Refrom Act of 2009"
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2009
In Q2, TCH Group, LLC lobbied for sanofi-aventis U.S. Inc. , earning $20,000. The report was filed on July 20, 2009.
Original Filing: 300189005.xml
Lobbying Issues
Coverage and payment issues for pharmaceuticals under consideration for draft legislation for healthcare reform; issues related to the importation of presecription drugs in amendments to the draft legislation "Affordable Health Choices Act"; issues related to a regulatory pathway and reimbursement for follow on biologics, including such provisions in HR 1548 "Pathway for Biosimilars Act:l issues related to awareness of the company's Access to Medicines Program; all provisions of H. Res. 231 "Supporting the goals andideals of 'Deep Vein Thrombosis Awareness Month'; general issues related to Medicare Part D program
Lobbying Issues
Issues related to the Medicaid program.
Medicare Part B Reimbursement
Lobbying Issues
Extension of the U.S. R&D tax credit including all such provisions in HR 422 "To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
All provisions of S369 "Protecting Access to Affordable Generic Drugs Act of 2009" and HR1706 "Protecting Consumer Access to Generic Drugs Act of 2009"; all provisions of S515 "The Patent Reform Act of 2009" and HR1260 "The Patent Reform Act of 2009"
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2009
In Q1, TCH Group, LLC lobbied for sanofi-aventis U.S. Inc. , earning $40,000. The report was filed on April 20, 2009.
Original Filing: 300162489.xml
Lobbying Issues
Cancer awareness, including women's cancer program; issues related to Deep Vein Thrombosis (DVT) awareness and quality of care; issues related to diabetes care in the federal healthcare programs; issues relating to a regulatory pathway and Medicare reimbursement for follow on biologics; Comparative effectiveness; General information related to Health Information Technology.
Lobbying Issues
Issues related to the Medicaid program.
Medicare Part B Reimbursement
Lobbying Issues
Provisions related to the R&D tax credit in S2209 "Research Credit Improvement Act of 2007"; HR 1424 "Emergency Economic Stabilization Act of 2009"; and S41 "Research Competitiveness Act of 2007"
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2008
In Q4, TCH Group (formerly Tongour Simpson Holsclaw and Cooney, LLC) lobbied for sanofi-aventis U.S. Inc. , earning $40,000. The report was filed on Jan. 21, 2009.
Original Filing: 300130503.xml
Lobbying Issues
Cancer awareness, including women's cancer program; issues related to Deep Vein Thrombosis (DVT) awareness and quality of care; issues related to diabetescare in the federal healthcare programs.
Lobbying Issues
Issues related to the Medicaid program.
Medicare Part B Reimbursement.
Lobbying Issues
Provisions related tot he R&D tax credit in S2209 "research Credit Improvement Act of 2007"; HR 1424 "Emergency Economic Stabilization Act of 2009"; and S41 "research Competitiveness Act of 2007"
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2008
In Q3, TCH Group (formerly Tongour Simpson Holsclaw and Cooney, LLC) lobbied for sanofi-aventis U.S. Inc. , earning $40,000. The report was filed on Oct. 20, 2008.
Original Filing: 300107557.xml
Lobbying Issues
Cancer awareness, including women's cancer program; issues related to Deep Vein Thrombosis (DVT) awareness and quality of care; issues related to diabetes care in the federal healthcare programs; and issues related to men's health
Lobbying Issues
Issues related to the Medicaid program
Lobbying Issues
provisions related to the R&D tax credit in S2209 "Research Credit Improvement Act of 2007"; HR1424 "Emergency Economic Stabilization Act of 2009"; and S41 " Research Competitiveness Act of 2007"
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2008
In Q2, TCH Group, LLC (formerly Tongour Simpson Holsclaw and Cooney, LLC) lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on July 21, 2008.
Original Filing: 300077861.xml
Lobbying Issues
Issues related to follow-on biologics, drug safety, importation/reimportation of prescription drugs, drug advertising, and the Citizen's Petition process, including such provisions in S1082 "The Food and Drug Administration Revitalization Act" and HR3580. "The Food and Drug Administration Amendment Act of 2007", and HR3610 "Food and Drug Safety Act of 2007"; HR 1038 "Access to Life-Saving Medicine Act" and S1695 "Biologics Price Competition and Innovation Act of 2007" All provisions.
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues and provisions related to the disclosure of the Medicare Part D donut hole and other improvements for beneficiaries of the Medicare program, and the Medicaid drug rebate, including such provisions in HR3162 "The Children's Health and Medicare Protection Act of 2007" and S1607, "The Children's Health Insurance Program Reauthorization Act of 2007." Coding and reimbursement of coverage issues for Medicare Part B products and Medicare Part D services, preventative health screenings and assessments, and obesity drugs; issues related to DVT prevention and awareness, including draft legislation "Deep Vein Thrombosis Prevention Act of 2007"; issues related to osteoporosis prevention, awareness, and screening. H.R. 6331, S. 3101, Medicare Improvements for Patients and Providers Act of 2008.
Lobbying Issues
HR 3610, "Food and Drug Import Safety Act of 2007"; S. 242, HR 380, "Pharmaceutical Market Access and Drug Safety Act of 2007"; H.R.2606 and S1736 "340B Program Improvement and Integrity Act of 2007"; HR 2680 "Health Care Access and Rural Equity Act of 2007"; S251 "Pharmaceutical Market Access Act of 2007"; S242 and HR380 "Pharmaceutical Market Access and Drug Safety Act of 2007" (provisions related to proposed changes to the 340B federal drug pricing program).
1st Quarter, 2008
In Q1, Tongour Simpson Holsclaw and Cooney, LLC lobbied for sanofi-aventis U.S. Inc. , earning $40,000. The report was filed on April 21, 2008.
Original Filing: 300049752.xml
Lobbying Issues
Issues related to follow-on biologics, drug safety, importation/reimportation of prescription drugs, drug advertising, and the Citizen's Petition process, including such provisions in S1082 "The Food and Drug Administration Revitalization Act" and HR3580. "The Food and Drug ADministration Amendment Act of 2007", and HR3610 "Fodd and Drug Safety Act of 2007"; HR1038 "Access to Life-Saving Medicine Act" and S1695 "Biologics Price Competition and Innovation Act of 2007" All provisions.
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues and provisions related to the closure of the Medicare Part D donut hole and other improvements for beneficiaries of the Medicare program, and the Medicaid drug rebate, including such provisions in HR3162 "The Children's Health and Medicare Protection Act of 2007 and S1607, "The Children's Health Insurance Program Reauthorization Act of 2007." Coding and reimbursement of coverage issues for Medicare Part B products and Medicare Part D services, preventative health screenings and assessments, and obesity drugs; issues relatd to DVT prevention and awareness, including draft legislation "Deep Vein Thrombosis Prevention Act of 2007"; issues related to osteoporosis prevention, awareness, and screening.
Lobbying Issues
Issues related to importation/reimportation of prescription drugs and the Labor HHS-Education Appropriations Act.
Lobbying Issues
HR 3610 "Food and Drug Import Safety Act of 2007"; S. 242, HR 380, "Pharmaceutical Market Access and Drug Safety Act of 2007", HR 2638, "Department of Homeland Security Appropriations Act, 2008"; H. AMDY 734 to HR 3161 and S1859 "agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2008" (provisions related to imporation of prescription pharmaceuticals, safety inspections of such products, and the adequacy to protect the American publicfrom counterfeit, adultered, and sub-potent products. HR2606 and S1376 "340B Program Improvement and Integrity Act of 2007"; HR380 "Pharmaceutical Market Access and Drug Safety Act of 2007" (provisions related to proposed changes to the 340B federal drug pricing program).
0th Quarter, 2007
In MM, Tongour Simpson Holsclaw and Cooney, LLC lobbied for SANOFI-AVENTIS PHARMACEUTICALS INC. , earning $60,000. The report was filed on Aug. 3, 2007.
Original Filing: 200045309.xml
Lobbying Issues
1. S. 334, HR 700, S. 1551, S. 109, HR 2744-Specifically, provisions relating to importation of prescription drugs.
2. S. 930- A bill to amend the Food and Drug Administration Safety Act, with respect to drug safety.
3. S. 1082-Prescription Drug User Fee Act & Drug Safety.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate